CRBUCaribou Biosciences, Inc.同业对比
Caribou Biosciences, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRBU本股 | $140M#9 | — | 1.4x#4 | 12.5x#6 | 11.7%#1 | 0.7%#7 | -1329.4%#6 | -151.0%#10 | — | — | -24.3%#6 | — |
| ABOS | $185M#2 | — | 3.2x#7 | — | — | -18.6%#10 | — | -211.9%#11 | -421.4%#2 | — | 103.2%#2 | — |
| DTIL | $179M#3 | — | 3.9x#10 | 5.2x#4 | -50.1%#4 | -738.0%#14 | -152.2%#3 | -101.0%#7 | — | — | 42.0%#3 | — |
| OTLK | $167M#4 | — | — | 118.0x#8 | — | 17.2%#6 | -4744.3%#7 | — | -12.8%#1 | — | -33.5%#9 | — |
| HUMA | $158M#5 | — | 5.0x#11 | 77.3x#7 | — | 72.5%#3 | -5306.0%#8 | -130.6%#9 | — | — | -62.9%#14 | — |
| ARMP | $155M#6 | — | — | — | — | -818.8%#15 | — | — | — | — | 41.5%#4 | 0.1%#1 |
| TNYA | $148M#7 | — | 2.1x#5 | — | — | 18.5%#5 | — | -130.5%#8 | — | — | -46.1%#12 | — |
| NMRA | $144M#8 | — | 3.2x#8 | — | — | -2.8%#9 | — | 532.2%#2 | -594.0%#3 | — | -46.3%#13 | — |
| LENZ | $129M#10 | — | 0.6x#2 | 6.8x#5 | — | -65.0%#11 | -477.5%#5 | -37.5%#4 | — | — | -90.2%#16 | — |
| ENGN | $127M#11 | 0.8x#1 | 0.6x#1 | — | — | -112.7%#12 | — | -50.9%#5 | — | — | -69.6%#15 | — |
| BDTX | $112M#12 | — | 1.2x#3 | 1.6x#2 | — | 132.1%#2 | 17.9%#2 | 23276.9%#1 | — | — | -38.2%#11 | — |
| ATTO | $1.1B#1 | — | — | — | — | — | — | — | — | — | 333.9%#1 | — |
| CGTX | $102M#13 | — | 3.1x#6 | — | — | 30.9%#4 | — | -71.1%#6 | — | — | -27.0%#7 | — |
| CRDF | $101M#14 | — | 3.8x#9 | 170.5x#9 | -13.2%#3 | -0.9%#8 | -8256.3%#9 | -0.2%#3 | — | — | -35.3%#10 | — |
| ATRA | $100M#15 | — | — | 0.8x#1 | -6.3%#2 | 138.3%#1 | 29.7%#1 | — | — | — | -16.2%#5 | — |
| PTHS | $84M#16 | — | — | 5.0x#3 | — | -444.6%#13 | -193.1%#4 | — | — | — | -30.3%#8 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议